SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

MacroGenics Reports Positive Interim Phase 2 LINNET Results

The company said single-agent lorigerlimab showed encouraging preliminary clinical activity in clear cell gynecologic cancer.

MGNX

Related stories